Given notable advantages of the ease of use, lower cost, and acceptance among patients [9, 10], the prevalence of glyburide use for GDM treatment increased from 7.4% in 2000 to 64.5% in 2011 in the USA; antidiabetic oral agents have replaced insulin as the more common pharmacotherapy for GDM over the past decades [8]. Here, INS is linked to gestational diabetes.